Zacks Research Upgrades Sysmex (OTCMKTS:SSMXY) to Hold

Sysmex (OTCMKTS:SSMXY) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Sysmex Trading Up 2.8%

OTCMKTS:SSMXY opened at $12.12 on Tuesday. The company has a market capitalization of $7.63 billion, a P/E ratio of 28.86 and a beta of 1.05. The stock’s 50 day moving average price is $9.85 and its 200 day moving average price is $9.20. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. Sysmex has a 52 week low of $8.01 and a 52 week high of $13.49.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Friday, August 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. The firm had revenue of $825.85 million during the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. On average, research analysts forecast that Sysmex will post 0.38 EPS for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.